Romania‘s drug producer Biofarm announced on Tuesday that it registered a turnover of RON 179 mln in the first nine months of 2021, an increase of 16% compared to the same period in the previous year and it recorded a net profit increase of 20% to RON 54.8 mln compared to the same period in 2020.
Biofarm stated that Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) reached RON 75.6 mln an increase of 20% compared to the first nine months of 2020.
Romania’s drug producer maintained its market share in volume with a 6% increase from the same period of 2020, in line with category development.
In value, Biofarm consolidated its sales to the final consumer, registering a 19% increase, compared to the purchase price in pharmacies.